DE60233936D1 - Therapeutische Zusammenseztungen zur Toleranzinduktion - Google Patents

Therapeutische Zusammenseztungen zur Toleranzinduktion

Info

Publication number
DE60233936D1
DE60233936D1 DE60233936T DE60233936T DE60233936D1 DE 60233936 D1 DE60233936 D1 DE 60233936D1 DE 60233936 T DE60233936 T DE 60233936T DE 60233936 T DE60233936 T DE 60233936T DE 60233936 D1 DE60233936 D1 DE 60233936D1
Authority
DE
Germany
Prior art keywords
tolerance induction
therapeutic
connections
therapeutic connections
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233936T
Other languages
English (en)
Inventor
Rodney William Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of DE60233936D1 publication Critical patent/DE60233936D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Magnetic Treatment Devices (AREA)
DE60233936T 2001-05-11 2002-05-10 Therapeutische Zusammenseztungen zur Toleranzinduktion Expired - Lifetime DE60233936D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0111497.4A GB0111497D0 (en) 2001-05-11 2001-05-11 Therapeutic methods
PCT/GB2002/002114 WO2002092064A2 (en) 2001-05-11 2002-05-10 Therapeutic method for inducing tolerance

Publications (1)

Publication Number Publication Date
DE60233936D1 true DE60233936D1 (de) 2009-11-19

Family

ID=9914421

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233936T Expired - Lifetime DE60233936D1 (de) 2001-05-11 2002-05-10 Therapeutische Zusammenseztungen zur Toleranzinduktion

Country Status (9)

Country Link
US (1) US20040214839A1 (de)
EP (1) EP1385550B1 (de)
JP (1) JP2004533443A (de)
AT (1) ATE444762T1 (de)
AU (1) AU2002256775A1 (de)
DE (1) DE60233936D1 (de)
ES (1) ES2356371T3 (de)
GB (1) GB0111497D0 (de)
WO (1) WO2002092064A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210741D0 (en) * 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
CA2512819A1 (en) * 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
WO2005009468A1 (ja) * 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
GB0324523D0 (en) * 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4127612A (en) * 1978-03-17 1978-11-28 Miles Laboratories, Inc. 19-Hydroxy PGE1 carbinol analogues
CN1041631C (zh) * 1993-06-21 1999-01-13 默里尔药物公司 用作炎症前细胞因子选择性抑制剂的新的碳环核苷药物
US6127378A (en) * 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2331844A1 (en) * 1998-05-07 1999-11-11 University Of Maryland, Baltimore A method for diagnosing and treating chronic pelvic pain syndrome
ES2311483T3 (es) * 1999-12-14 2009-02-16 Genentech, Inc. Anatagonista del tnf-alfa y antagonista del lfa-1 para el tratamiento de la artritis reumatoide.
EP1199074A1 (de) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
DE10064991A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Pharmazeutische Formulierung enthaltend Thienopyrimidine und Prostaglandine oder Prostaglandinderivate (2)
GB0210741D0 (en) * 2002-05-10 2002-06-19 Medical Res Council Methods of therapy

Also Published As

Publication number Publication date
US20040214839A1 (en) 2004-10-28
GB0111497D0 (en) 2001-07-04
EP1385550B1 (de) 2009-10-07
ES2356371T3 (es) 2011-04-07
JP2004533443A (ja) 2004-11-04
ATE444762T1 (de) 2009-10-15
AU2002256775A1 (en) 2002-11-25
WO2002092064A2 (en) 2002-11-21
WO2002092064A3 (en) 2003-04-10
EP1385550A2 (de) 2004-02-04

Similar Documents

Publication Publication Date Title
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MY169308A (en) Treatment of tnf? related disorders
MY146986A (en) Methods for treating interleukin-6 related diseases
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NZ617083A (en) Combination therapy for the treatment of ocular neovascular disorders
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
ATE400573T1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
DK1401415T3 (da) Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
TW200508233A (en) Chk-1 inhibitors
DE60233936D1 (de) Therapeutische Zusammenseztungen zur Toleranzinduktion
WO2003094957A3 (en) Methods of therapy for inducing tolerance
IS2331B (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
CY1107965T1 (el) Παρασκευασμα λεκτικων ιξου για στοματικη ληψη και μεθοδος
ATE329898T1 (de) Kombinationspräparat zur therapie von immunologischen erkrankungen
SE0101257D0 (sv) Treatment of whiplash associated disorder
DE60233819D1 (de) Doppelester
UA36840A (uk) Спосіб лікування хронічних гепатитів різного генезу
AU2013204147B2 (en) Treatment of TNFalpha related disorders
UA38352A (uk) Засіб для лікувальних ванн
UA38418A (uk) Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
DK1299350T3 (da) Substituerede benzamider til styrket immunforsvar og behandling af kræft, infektioner og manio-depressive sygdomme
UA51058A (uk) Спосіб лікування уражень суглобів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition